BioSpace News Archive

iTeos Therapeutics, Inc. announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company’s audit committee.

CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT.

Invitae, a leading medical genetics company, announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn.

BrainsWay Ltd., a world leader in advanced and non-invasive treatment for brain disorders, reported fourth quarter and full-year 2023 financial results and provided an operational update.

Biogen Inc. announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy who have unmet clinical needs after treatment with Zolgensma®.

BiomX Inc. today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”).

Spinal muscular atrophy, or SMA, is the leading genetic cause of infant death. Less than a decade ago, Cold Spring Harbor Laboratory Professor Adrian Krainer showed this brutal disease can be treated by tweaking a process called RNA splicing.

Fusion Pharmaceuticals Inc. today announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 245,300 shares.

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure, announced positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Guardant Health, Inc. announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant date of February 26, 2024 under the Guardant Health, Inc.